5'-O-methylcytidine | 50664-27-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5'-O-methylcytidine
• 英文别名: 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(methoxymethyl)oxolan-2-yl]pyrimidin-2-one
• CAS: 50664-27-2
• 化学式: C₁₀H₁₅N₃O₅
• 分子量: 257.246
• InChiKey: AQZIBVNEPZLCGR-ZOQUXTDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5'-O-methylcytidine 在 sodium hydroxide 作用下， 生成 5′-O-acetyluridine
  参考文献：
  名称：

  Lönnberg; Suokas; Käppi, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1986, vol. 40, # 10, p. 798 - 805

  摘要：

  DOI：

文献信息

• [EN] DELIVERY OF TARGET SPECIFIC NUCLEASES<br/>[FR] ADMINISTRATION DE NUCLÉASES SPÉCIFIQUES À UNE CIBLE
  申请人：SANGAMO THERAPEUTICS INC

  公开号：WO2018107026A1

  公开（公告）日：2018-06-14

  Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.

  本发明描述了包含阳离子脂质和其他脂质的脂质纳米颗粒，以及包含工程核酸酶以促进核酸向细胞的转移。
• [EN] TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION<br/>[FR] TECHNOLOGIES UTILES POUR LA PRÉPARATION D'OLIGONUCLÉOTIDES
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2020191252A1

  公开（公告）日：2020-09-24

  Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.

  除其他事项外，本公开提供了寡核苷酸制备技术，特别是手性控制的寡核苷酸制备技术，这些技术大大提高了粗品纯度和产量，并显著降低了制造成本。
• HCV NS3 protease inhibitors
  申请人：Holloway Katharine M.

  公开号：US20070027071A1

  公开（公告）日：2007-02-01

  The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

  本发明涉及一种公式（I）的大环化合物，该化合物可用作乙型肝炎病毒（HCV）NS3蛋白酶的抑制剂，其合成以及用于治疗或预防HCV感染的用途。
• [EN] SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS<br/>[FR] NUCLEOSIDE SUBSTITUE ET ANALOGUES NUCLEOTIDIQUES
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2010108140A1

  公开（公告）日：2010-09-23

  Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates.

  本文披露了具有保护磷酸酯基团的核苷酸类似物，以及合成具有保护磷酸酯基团的核苷酸类似物的方法，以及利用具有保护磷酸酯基团的核苷酸类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或症状的方法。
• Antiviral Activity of Novel Bicyclic Heterocycles
  申请人：De Jonghe Steven

  公开号：US20130190297A1

  公开（公告）日：2013-07-25

  The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加盐物和/或其立体异构体和/或其溶剂合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，并且涉及使用这些化合物来治疗或预防病毒感染以及用于制造用于治疗或预防病毒感染的药物，特别是属于逆转录病毒科、黄病毒科和小核病毒科家族的RNA病毒感染，更具体地是与人类免疫缺陷病毒1（HIV1）、人类免疫缺陷病毒2（HIV2）、丙型肝炎病毒（HCV）、登革病毒以及柯萨奇病毒、鼻病毒和脊髓灰质炎病毒等肠病毒感染相关的感染。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防病毒感染。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗病毒性疾病和病理状况的药物，例如但不限于与人类免疫缺陷病毒1（HIV1）、人类免疫缺陷病毒2（HIV2）、丙型肝炎病毒（HCV）、登革病毒以及柯萨奇病毒、鼻病毒和脊髓灰质炎病毒相关的病毒感染。